Literature DB >> 20974996

The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.

Talat H Malik1, Andrea Cortini, Daniele Carassiti, Joseph J Boyle, Dorian O Haskard, Marina Botto.   

Abstract

BACKGROUND: The early components of the classical and lectin complement pathways have been shown to protect low-density lipoprotein receptor-deficient mice (Ldlr(-/-)) from early atherogenesis. However, the role of the alternative pathway remained unknown, and that was investigated in this study. METHODS AND
RESULTS: Mice lacking factor B (Bf(-/-)), the initiator of the alternative pathway, were crossed with Ldlr(-/-) mice and studied under different proatherogenic conditions. There was no statistically significant difference in lipid profiles or atherosclerotic lesion development between Bf(-/-)/Ldlr(-/-) and Ldlr(-/-) mice fed a low-fat diet. However, in these groups, administration of bacterial lipopolysaccharide led to a significant increase in atherosclerosis only in Ldlr(-/-) and not in Bf(-/-)/Ldlr(-/-) mice, indicating that the alternative pathway is necessary for endotoxin-mediated atherogenesis. Bf(-/-)/Ldlr(-/-) mice also had significantly decreased cross-sectional aortic root lesion fraction area and reduced lesion complexity compared with Ldlr(-/-) animals after a 12-week period of high-fat diet, although this was also accompanied by reduced levels of serum cholesterol. Under both experimental conditions, the atherosclerotic changes in the Bf(-/-)/Ldlr(-/-) mice were accompanied by a marked reduction in complement activation in the circulation and in atherosclerotic plaques, with no statistically significant differences in immunoglobulin G deposition or in the serum antibody response to oxidized low-density lipoprotein.
CONCLUSIONS: These data demonstrate that amplification of complement activation by the alternative pathway in response to lipopolysaccharide or high-fat diet plays a proatherogenic role.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974996      PMCID: PMC2978131          DOI: 10.1161/CIRCULATIONAHA.110.981365

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  Innate and acquired immunity in atherogenesis.

Authors:  Christoph J Binder; Mi-Kyung Chang; Peter X Shaw; Yury I Miller; Karsten Hartvigsen; Asheesh Dewan; Joseph L Witztum
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

3.  Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study.

Authors:  C J Wiedermann; S Kiechl; S Dunzendorfer; P Schratzberger; G Egger; F Oberhollenzer; J Willeit
Journal:  J Am Coll Cardiol       Date:  1999-12       Impact factor: 24.094

4.  ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5.

Authors:  S Patel; E M Thelander; M Hernandez; J Montenegro; H Hassing; C Burton; S Mundt; A Hermanowski-Vosatka; S D Wright; Y S Chao; P A Detmers
Journal:  Biochem Biophys Res Commun       Date:  2001-08-10       Impact factor: 3.575

5.  Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice.

Authors:  Linda Persson; Jan Borén; Anna-Karin L Robertson; Ville Wallenius; Göran K Hansson; Marcela Pekna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-04-01       Impact factor: 8.311

Review 6.  Critical review of acylation-stimulating protein physiology in humans and rodents.

Authors:  Katherine Cianflone; Zhunan Xia; Lan Ying Chen
Journal:  Biochim Biophys Acta       Date:  2003-01-31

7.  Influence of C3 deficiency on atherosclerosis.

Authors:  Chiara Buono; Carolyn E Come; Joseph L Witztum; Graham F Maguire; Philip W Connelly; Michael Carroll; Andrew H Lichtman
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

8.  High expression of complement components in omental adipose tissue in obese men.

Authors:  Britt G Gabrielsson; Jenny M Johansson; Malin Lönn; Margareta Jernås; Torsten Olbers; Markku Peltonen; Ingrid Larsson; Lars Lönn; Lars Sjöström; Björn Carlsson; Lena M S Carlsson
Journal:  Obes Res       Date:  2003-06

Review 9.  Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells.

Authors:  F Niculescu; H Rus
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

10.  A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo.

Authors:  P R Taylor; A Carugati; V A Fadok; H T Cook; M Andrews; M C Carroll; J S Savill; P M Henson; M Botto; M J Walport
Journal:  J Exp Med       Date:  2000-08-07       Impact factor: 14.307

View more
  21 in total

Review 1.  Are toll-like receptors potential drug targets for atherosclerosis? Evidence from genetic studies to date.

Authors:  Christopher P Nelson; Clett Erridge
Journal:  Immunogenetics       Date:  2018-10-16       Impact factor: 2.846

Review 2.  [Microbiome, diabetes and heart: a novel link?]

Authors:  B A Kappel; M Lehrke
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

3.  Saturated fatty acid combined with lipopolysaccharide stimulates a strong inflammatory response in hepatocytes in vivo and in vitro.

Authors:  Yanchun Li; Zhongyang Lu; Ji Hyun Ru; Maria F Lopes-Virella; Timothy J Lyons; Yan Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-07-10       Impact factor: 4.310

4.  Cooperative stimulation of atherogenesis by lipopolysaccharide and palmitic acid-rich high fat diet in low-density lipoprotein receptor-deficient mice.

Authors:  Zhongyang Lu; Yanchun Li; Colleen W Brinson; Maria F Lopes-Virella; Yan Huang
Journal:  Atherosclerosis       Date:  2017-09-09       Impact factor: 5.162

Review 5.  The role of complement activation in atherogenesis: the first 40 years.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

6.  A zebrafish model for uremic toxicity: role of the complement pathway.

Authors:  Nathaniel Berman; Melisa Lectura; Josh Thurman; James Reinecke; Amanda C Raff; Michal L Melamed; James Reinecke; Zhe Quan; Todd Evans; Timothy W Meyer; Thomas H Hostetter
Journal:  Blood Purif       Date:  2013-05-08       Impact factor: 2.614

Review 7.  Gut microbiome and cardiometabolic risk.

Authors:  Ben Arpad Kappel; Massimo Federici
Journal:  Rev Endocr Metab Disord       Date:  2019-12       Impact factor: 6.514

8.  Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.

Authors:  Zhongyang Lu; Yanchun Li; Wing-Kin Syn; Zhewu Wang; Maria F Lopes-Virella; Timothy J Lyons; Yan Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-12-10       Impact factor: 4.310

Review 9.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

10.  Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia.

Authors:  Myles J Lewis; Talat H Malik; Liliane Fossati-Jimack; Daniele Carassiti; H Terence Cook; Dorian O Haskard; Marina Botto
Journal:  Arthritis Rheum       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.